Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

Countless investors and investment advisors are losing significant money because they are stuck in the orthodox thinking that ...

AJ Tracey and Jorja Smith join Rickie, Melvin and Charlie in the Live Lounge.

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

John Fetterman (D-Pa.) on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare ...

Apr 9, 2025 at 9:32 am ET • 1 min read As much as I don't want to believe it, I think the New York Giants will tie the team's fate going forward to Russell Wilson and Jameis Winston and pass on ...

Competitive Advantage: Zepbound vs. Wegovy Eli Lilly’s Zepbound is one of two GLP-1 drugs approved to treat obesity. The other, Wegovy, is marketed by Novo Nordisk (NVO), a global pharmaceutical ...

The study also included people who did not plan to take a GLP-1. The current market for GLP-1s approved by the FDA for weight management includes Saxenda, Wegovy, Ozempic, Zepbound and Monjaro.

Prescription weight loss medications, including GLP-1 agonists, orlistat, and Contrave, may be effective for some people. But other lifestyle changes are still necessary for long-term success.

A second unvaccinated child in Texas has died from measles, amplifying fears that the outbreak there could be wider than reported. The death, announced on 6 April, also harks back to a pre-vaccine ...

(WSVN) - A South Florida man was driven to take action after, he says, investigators took too long to track down his stolen truck. His own search steered him hundreds of miles away from home.

Novo Nordisk (NVO), the company behind Ozempic and Wegovy, announced that it will invest 6.4 billion reais (about $1.09 billion) in Brazil to increase production at its facility in Minas Gerais.